Synexus has augmented its clinical research services with the acquisition of new Doppler Ultrasound equipment for its research centres in the UK.
The Manchester-based multinational firm has installed the machines in each of its seven British centres, a move which will help it to continue increasing the number of patients it recruits annually for clinical studies.
Synexus has provided training to its doctors and staff in clinical research jobs
to use the new equipment, giving them better control over volumes and timing when conducting studies.
The machines will now be used in a new clinical trial for type 2 diabetes patients, in order to confirm diagnoses of peripheral artery disease.
Michael Fort, Synexus' chief executive, said: "We need to show GPs that we really can make a difference to their patients by delivering faster diagnoses and first-class medical care whilst their patients are part of our studies."
Synexus' clients include major pharmaceutical sector employers such as Abbott, Sanofi-aventis and GlaxoSmithKline, as well as CROs including Parexel and Quintiles.